- LOGIN
- MemberShip
- 2025-12-25 21:24:36
- Policy
- The answer is to improve the drug price system
- by Lee, Hye-Kyung Sep 24, 2020 06:20am
- The drug price system should be improved in order to enhance patient access to new drugs such as cancer and rare disease treatments. Through the 'non-face-to-face discussion to enhance patient accessibility of new drugs in the era of COVID-19' hosted by Lee Yong-ho, a member of the National Assembly and hosted by the Future Health Network on the 23rd, clinical field experts, patients, and pharmaceutical companies gathered opinions about ▲Flexible application of ICER values ▲ Risk-sharing system and expanded exemption from economic feasibility evaluation ▲ Post-priority evaluation ▲ Generic drug price cut ▲ Separate fund. The government also acknowledged the need to improve the drug price system, but emphasized that limited in reality. Lee Hyung-ki, a professor of clinical pharmacology at Seoul National University Hospital, who was in charge of the topic presentation, said, "Economic evaluation is difficult or the ICER value should be flexibly applied in the form of a band for cancer and severe disease treatments, and it still took 746 days for the total drug to pay and 729 days for the risk-sharing system, so there is no difference, but there is no alternative to the risk-sharing system." Choi Young-hyun, honors professor at Korea national university of Welfare (former head of the Department of Welfare) also said, "In the case of anticancer drugs, it takes 757 days to pay. Patients and their families have no choice but to mourn." After paying, in the process of negotiating a drug price with the NHIS, the method of adjusting the amount of use through drug price linkage can be an alternative." Choi In-hwa, managing director of Roche Korea (Chairman of the KRPIA reimbursement improvement Subcommittee) said that under the current situation, listing new drugs with Korea as a priority would be difficult for global pharmaceutical companies. Managing Director Choi added, "Korea is a country that can invest in new drugs because of the late payment of reimbursement and the high prices. We need to secure various solutions such as improving the drug price system such as total amount or positive list system for new drugs.“ On behalf of the patient, Baek Min-hwan, the representative of the Korea Multiple Myeloma Patients Association, asked about the government's measures to improve the RSA system and pay ultra-high-priced anticancer drugs. CEO Baek suggested, "It takes too long to be registered for benefits after approval. Patients are told to increase accessibility through positive list system altogether rather than waiting for them to die." The health authorities also sympathized with this, but said that there were some differences in perception. "The flexible application of the ICER value is simpler or not easier than expected, and it is good in terms of reinforcing guarantees, but we have to consider rising drug prices." said Choi Gyeong-ho, the secretary of the MOHW's insurance drug department. However, he said that the system could be supplemented by continuously collecting opinions. Kim Ae-ryeon, head of the pharmaceutical management department of the HIRA, said that she would release a proposal to improve the ICER value sooner or later. Kim said, "We are conducting a study on the ICER threshold, and we will be able to disclose the improvement plan once it is finished." Regarding the expansion of the economic evaluation exemption, she explained that as of June this year, 17 ingredients and 28 items were registered as an economic evaluation omission system. The NHIS also promised to prepare a mechanism for transparency in drug price negotiations by the second half of this year so that it can escape from 'drug price negotiations that are not known at all'. While negotiating drug prices, Park Jong-heon, head of the NHIS' reimbursement strategy department, said that we should have disclosed data such as the status of reimbursement and price hikes due to increased usage, and transparently disclose data to review if there is a disagreement. He said, “Until now, there were restrictions due to personal information protection or infringement of third party rights, and we will make a track on the part that can be shared as much as possible until the second half of the year so that there is no talk of negotiating without knowing anything.” On the other hand, the MOHW mentioned re-evaluation of registered materials regarding the expansion of insurance finances to strengthen access to new drugs. Choi said, "The overall health care budget is about ₩19 to 20 trillion, but it is impossible to set a budget for how much to spend in a certain field, through a reasonable increase in health care costs or re-evaluation of drugs such as Choline alfoscerate, and it will be possible to expand the coverage of cancer or rare diseases." In connection with the point of YouTube viewers that the Severe Disease Deliberation Committee of the HIRA is struggling to pay for cost-effectiveness, Choi said, “We cannot help but consider the overall cost of health care while judging the usefulness of the new drug in cancer, and tt any stage, we have to judge the cost.”
- Policy
- Certican keeps weighted pricing for now, Samsca lowered 30%
- by Kim, Jung-Ju Sep 24, 2020 06:19am
- Novartis Korea’s immunosuppressant Certican (everolimus) has ultimately dodged the double pricing reduction. Although dismissed from patent litigation and lost from the administrative litigation against the government, the immunosuppressant is to keep its premium pricing benefit as stipulated by the policy that sustains the benefit when the number of companies with same substance drugs is three or less. The pricings on Relestat eye drops 0.05% (epinastine hydrochloride) by Allergan Korea and Samsca tablet (tolvaptan spray dry powder) by Korea Otsuka Pharmaceutical would be lowered by 30 percent from next month as authorized by the government. Nevertheless, the pricings would be lowered 23.5 percent more a year later as they lose the premium pricing. The pharmaceutical industry sources reported South Korea’s Ministry of Health and Welfare is in process of reflecting the said changes on the List of Reimbursed Drugs and Upper Limit Pricing. The finalized listed would come in effect from Oct. 1. First, Daewon Pharmaceutical’s Codaewon S syrup and Kisan Pharma’s Paricitol injection would receive weighted pricing of 21.2 percent and 10 percent, respectively, for a year. For a first generic, the South Korean government grants pricing of 59.5 percent of the original for a year from the date of listing. The pricing goes up to 68 percent for generics by an Innovative Pharmaceutical Company. But if the number of generic companies is three or under, the weighted pricing would be maintained until another company launches the generic. As for a latecomer generic listed within a year the first generic is listed, the same premium pricing would be granted for a year from the point of the first generic listing. The weighted pricing on Codaewon S syrup and Paricitol injection would expire on Oct. 1 and Apr. 1 next year, respectively. Total five items would get to keep their premium pricing benefit. The premium on Novartis’ Certican tablet would be maintained for all doses. In fact, Certican has undergone a pricing reduction once this month, as its patent litigation was rejected and it lost the litigation against the government regarding the pricing reduction order. The pricing on Novartis’ drug was supposed to drop with expired premium benefit, but its initial weighted pricing would remain unchanged as long as the same substance generic-supplying companies are three or less. Along with Certican, Myungmoon Pharm’s Taro Ammonium Lactate Lotion 12% would also keep its weighted pricing. The government authorized the 30-percent pricing reduction on Allergan Korea’s Relestat eye drops 0.05% and Korea Otsuka Pharmaceutical’s Samsca tablet, effective next month. The government-authorized pricing reduction is applied to first-in-class drugs and products with same administration route, substance and formula, when a generic is listed. But when the first generic is listed, the first-in-class drug’s pricing is brought down to 53.55 percent but the premium benefit keeps the pricing at 70 percent of the initial pricing for a year. The upper limit pricing of Relestat eye drops 0.05% would be revised to 7,213 won, originally at 10,305 won, while the pricings on Samsca tablet 15 mg and 30 mg would be adjusted from 14,366 won to 10,056 won and from 14,400 won to 10,080 won, respectively. The premium pricing benefit would be dropped from Sept. 1 next year, automatically reducing their pricings by 23.5 percent, each. Two products’ pricings would be voluntarily lowered as requested by respective companies. The government allows adjustment of listed drug’s upper limit pricing, when a manufacturer, CMO, or importer requests to lower the pricing as a part of sales strategy or due to a corporate circumstances. The pricings on Newmantine tablet by Korea Prime Pharm and Pamcirac tablet by Ildong Pharmaceutical would be lowered by 17.2 percent and 2.6 percent, respectively, from next month.
- Policy
- Italian-made Gliatirin and Vesseldue-F efficacy questioned
- by Lee, Tak-Sun Sep 23, 2020 06:21am
- ‘Aju Vesseldue-F Soft Capsule A series of drugs from Italian manufacturers are in a tight spot, as they have been selected as an efficacy reevaluation subjects. These drugs do not have sufficient evidence to prove the efficacy, because they hardly have much records of use in countries other than South Korea. The pharmaceutical industry sources reported on Sept. 20, South Korea’s Ministry of Food and Drug Safety (MFDS) has unveiled its plan to conduct clinical reevaluation on three drugs. In last January, June and August, Kolmar Pharma’s cinnarizine, choline alfoscerate and heparinoids received order to undergo reevaluation, respectively. Particularly, the public’s spotlight was on reevaluation for cognitive function enhancer choline alfoscerate with the biggest market value in Korea, and anticoagulant heparinoids. Both the original choline alfoscerate Gliatirin and the best-selling heparinoids Vesseldue-F have been developed by Italian pharmaceutical companies. An Italian-based Italfarmaco developed Gliatirin and signed a license with Daewoong Pharmaceutical in 2000 for the marketing in Korea. Currently, the deal has been taken over by Chong Kun Dang. Choline alfoscerate, the main substance of Gliatirin, generates 300 billion won annually in Korea. However, the drug’s sales in some countries have been restricted, except in South Korea and Italy. While the drug is used as a health supplement in the U.S., most of the choline alfoscerate products have been withdrawn from the Japanese market after reevaluation. Learning from those countries, Korean Pharmacists for Democratic Society and other civic groups raised the issue and the National Assembly audit last year questioned the medicine’s efficacy. In early this year, the drug was called out for reevaluation and the government put limitation on the use. The clinical reevaluation was also ordered on heparinoids as their uses in foreign countries raised questions. One of heparinoids, Vesseldue-F (sulodexide) sold by Aju Pharm in Korea, is a bestseller generating 25 billion won annually. A heparin antagonist, heparinoids are extracted from porcine cartilage. The substance is known to have anticoagulant effect like heparin. In the recently disclosed minutes from Central Pharmaceutical Affairs Deliberation Committee discussing the heparinoids clinical reevaluation, experts apparently mentioned of the need for the drug use. An expert participating in the meeting pointed out, “It is true that latest evidences in efficacy of heparinoids are insufficient,” but also defended the drug by stating “The drug has been used frequently in the past, and has relatively low bleeding tendency compared to antiplatelets agent.” Another expert elaborated, “Heparinoids are used to treat peripheral vascular and venous diseases. Although the drug lacks vast amount of evidence of improving survival rate, the drug still has evidence of improving the symptoms of those disease,” and “in some cases, patients with phlebothrombosis switch to heparinoids after using NOAC for six months.” The heparinoids market leader, Vesseldue-F was first developed by an Italian company Alfa-Wassermann. Aju Pharm licensed in the technology and received the Korean health authority’s approval in 1997 under the name of ‘Aju Vesseldue-F Soft Capsule.’ Italy is one of A8 countries MFDS refers to when reviewing pharmaceuticals. Drugs with use history from the A8, consisting of the U.S., the U.K., France, Italy, Japan, Germany, Switzerland and Canada, are highly likely to pass the license renewal review. Choline alfoscerate was able to renew the license in 2018 with its prescription history from Italy. But as clinical reevaluations were recently ordered on two Italian-made drugs, some claim the A8 roster should be revisited. A pharmaceutical industry insider commented, “Coincidentally, a couple of drugs made by Italian companies have been controversial with their efficacy,” and “because a number of drugs developed in Italy are old, some countries have started not using them.”
- Policy
- Generic companies for Atozet are interested in contractors
- by Lee, Tak-Sun Sep 22, 2020 06:27am
- Atozet It is known that generic companies of the hyperlipidemia complex Atozet(Atorvastatin-Ezetimibe, Chong Kun Dang) will sign a consignment contract with Chong Kun Dang today (22nd). Generic companies are paying attention to the number of final contractors and scrutinizing their strengths and weaknesses. According to the industry on the 21st, Chong Kun Dang requested that the contract be revealed by the 18th after holding a consignment meeting on the 16th. And it is reported that the final contract will be made on the 22nd. Chong Kun Dang is recruiting 21 consignment companies. However, generic companies seem to be struggling until the last minute because the number of companies may decrease at the time of the final contract. However, most of them are expected to proceed with the contract. The reason they are interested in the number of companies is that the price of drugs varies depending on the number. In the new cascading drug price system, they can get high prices up to 20 items or less. Drug prices drop from 21 in the order of listing. However, if only 17 companies participate in the entrustment, A total of 19 items will be listed, including the original Atozet and Chong Kun Dang's incrementally modified drug(IMD). Therefore, the next generic also has an opportunity to receive high drug prices. The company entrusted with the first generic company, which is listed after the bioequivalence test, is also licensed at the same time, so it can receive high drug prices. The industry expects that consignees such as Dongkoo Bio&Pharma will enter the market by applying for permission after the PMS expires in January next year. Even if the entry order is late, it is an opinion that if the drug price is the same as that of Chong Kun Dang, it is not bad to belong to the generic group that goes through bioequivalence test. This is because the commissioned production cost of generic group, which had bioequivalence test, is lower. Due to such a complex formula, various theories are arising in the industry, such as a dual contract between Chong Kun Dang and Dongkoo Bio&Pharma. However, no content has been confirmed yet. The reason why it is so difficult to decide on generics for Atozet is that the cascade drug prices system, which has been in force since last July, are acting as a final blow. According to this system, up to 20 items in the order of listing will receive 53.55% of the drug price compared to the original if the conditions such as bioequivalence test and the use of DMF are met. However, starting from 21 generics, the order of approval became important as drug prices were calculated at 85% of the lowest price. Generic for Atozet that have been tested for bioequivalence can apply for permission in time for the expiration of PMS in January next year. However, Chong Kun Dang product that has undergone clinical trial is not generic, but is a drug for data-based re-evaluation, so it is expecting final approval in October. Chong Kun Dang is conducting a commissioned generics consignment production project that recruits consignors through grant (data sharing) and can enter more quickly than generics. Chong Kun Dang's products and delegated generics receive preferential drug prices over generics that have been tested for bioequivalence because they are listed in a faster order.
- Policy
- ORR 100%, Phase III of Lazertinib combination was approved
- by Lee, Tak-Sun Sep 22, 2020 06:26am
- The clinical trial of Lazertinib-Amivantamab, which was released by Janssen at the European Society for Medical Oncology (ESMO) on the 20th, is also being conducted in Korea. As a result of this interim study, the response rate (ORR) was 100%, raising expectations as a treatment for non-small cell lung cancer that threatens Tagrisso. Lazertinib is a new drug developed by Yuhan in Korea and exported to Janssen, a multinational pharmaceutical company. On the 21st, the MFDS approved a multinational phase III clinical trial for the combination of 'Lazertinib (JNJ-73841937)' and Amivantamab submitted by Janssen Korea. Lazertinib is a 3rd generation tyrosine kinase inhibitor (TKI) candidate, and Amivantamab is a bispecific antibody targeting EGFR-MET. This trial is the primary treatment for clinical trial subjects with local advanced or metastatic non-small cell lung cancer with EGFR mutations. Osimertinib, generic for Tagrisso versus Lazertinib compared to the combination therapy of Amivantamab and Lazertinib. This is a phase III, randomized clinical trial. 8 were domestic patients of the total 120 subjects. The examination will be conducted at Seoul National University Bundang Hospital, Samsung Medical Center, Seoul National University Hospital, and Shinchon Severance Hospital. Earlier, Janssen revealed the results of an interim analysis of the clinical trial of combination of Lazertinib-Amivantamab at the ESMO 2020 online meeting on the 20th at local time. According to the published contents, the combination therapy of 'Lazertinib-Amivantamab showed a high response rate in the patient group (45 patients) among the non-small cell lung cancer patients with EGFR exon 19 defect or L858R mutation, a group of patients without prior treatment experience (20 patients) and 3rd generation TKI 'Tagrisso' (Osimertinib) showed recurrence after taking. For patients without prior treatment experience, such as EGFR-targeted anticancer drugs, tumors in all 20 patients reduced and the objective response rate (ORR) was 100% (95% CI, 83-100) when evaluated at 7 months (median, range 3-19 months) after drug treatment. In addition, among patients who showed recurrence after administration of Tagrisso, the tumor size decreased in 16 patients. According to the clinical results, Lazertinib-Osimertinib is expected to be the next treatment for patients who are resistant to Tagrisso and as a first-line treatment.
- Policy
- Goal of generic for Atozet is to be approved in next January
- by Lee, Tak-Sun Sep 22, 2020 06:26am
- Atozet by MSDChong Kun Dang's consignment-produced hyperlipidemia combination drug 'Atozet (Atorvastatin-Ezetimibe) is known to have applied for approval this month and is aiming for approval in next January. In that Atozet’s PMS by MDS will expire in next January, it is faster to acquire product approval than generics that have undergone bioequivalence testing. Accordingly, it will be advantageous in terms of drug prices. Chong Kun Dang recently held a meeting with 21 outsourced companies and announced plans to proceed with item approval. Chong Kun Dang applied for approval of a drug with the same ingredients as Atojet, which had undergone its own clinical trial in April. This drug is expected to be approved as a drug for data-based re-evaluation in October. At the same time, it is expected to receive Atozet's remaining PMS (expired on January 22, 2021). Prior to this, Chong Kun Dang recruited 21 consignment companies for the drug. It is known that the selection of 21 companies was referred to in the order of sales of Atorvastatin formulations. It is reported that on the 16th, at the consignee meeting, the details of the item permission plan were announced. According to the industry, the consignment item plans to complete the application for permission this month and obtain an item approval in next January. After going through the insurance payment process, it will start selling from April. In this case, after the expiration of PMS in January, it will enter the market ahead of generics that apply for permission. In addition, the price of drugs is expected to be higher than those of generics depending on the cascade drug prices system. Chong Kun Dang's self-developed drug for data-based re-evaluation is expected to be approved in October. However, it is known that Chong Kun Dang will not release it first, but will sell it at the same time as the consignment companies. However, as Chong Kun Dang is currently jointly selling the original 'Atozet' with MSD, it is unclear whether Chong Kun Dang will directly release the generic. Accordingly, some say that it is highly likely to pass the sale of drugs developed after Chong Kun Dang to other companies. Atozet is a large-scale drug that recorded an outpatient prescription of ₩63 billion last year. With Chong Kun Dang's product development and PMS expiration, it is expected to turn into a competitive system from next year. However, since various interests such as drug price issues and co-promotion are complicated, it is expected that each company will have a great deal of effort in establishing strategies.
- Policy
- Acromegaly and Huntington’s disease drugs win approval
- by Lee, Tak-Sun Sep 21, 2020 06:12am
- The South Korean health authority granted licenses for Pfizer Pharmaceutical Korea and Teva Handok, respectively. Pfizer’s acromegaly treatment and Teva Handok’s Huntington’s disease treatment would be now accessible to the patients in need of treatment. The Ministry of Food and Drug Safety (MFDS) granted approval on Somavert (pegvisomant) by Pfizer Pharmaceutical Korea and Austedo (deutetrabenazine) by Teva Handok as of Sept. 16. Somavert injection is an incrementally modified drug with evidence submitted, whereas Austedo tablet is a novel drug. Somavert is used to treat adults with acromegaly and intolerance or resistance in normalizing insulin-like growth factor 1 (IGF-1) with somatostatin analogues, and who respond inadequately to surgery or radiation. Acromegaly is a hormonal disorder that enlarges hands, feet, forehead, and jaw as excessive level of growth hormone is excreted even after the growth plates have been closed. About 60 out of one million people are diagnosed with the rare diseases, and usually the diagnosis is made from forties. The main cause of the disorder is excess growth hormone produced by benign tumor in the pituitary gland. However, relevant studies have not found the cause of the tumor, yet. The recommended treatment is to remove the tumor in the pituitary gland with a surgery, but when the tumor is too big and cannot be removed completely, the patient has to receive radiation therapy and growth hormone-inhibiting medication simultaneously. But many of the patients do not respond well to growth hormone-inhibiting drug, so the demand for more fundamental treatment is high. The newly approved Somavert is a recombinant analogue of the human growth hormone, which blocks the growth hormone receptor and impedes signal transduction. During a clinical trial conducted with 112 acromegaly patients, Somavert demonstrated statistically significant improvement in overall symptoms and relevant indicators than the placebo. And approximately 93 percent of trial participants reached normalized IGH-1 level for 42.6 weeks. Also approved on the same day, Austedo is a new drug used to treat symptoms of Huntington’s chorea, a kind of inherited diseases. The Huntington’s disease is a rare progressive brain disorder caused by a mutated gene on chromosome 4. According to Health Insurance Review and Assessment (HIRA), there were 286 patients with Huntington’s disease reported in South Korea as of 2018. The most common symptom, also known as chorea, is abnormal motor behavior like sudden involuntary muscle spasms. Approximately 90 percent of the patients with Huntington’s disease show the symptom. Austedo conducted a clinical trial with 90 Huntington’s disease patients having chorea, but who can walk by themselves. The trial compared the drug against placebo and confirmed the drug’s statistically significant effect with the evaluation indicator score. The patient group taking Austedo reached 4.4 points, while the placebo group marked 1.9 points.
- Policy
- Cancer Fund Act is promoted
- by Lee, Jeong-Hwan Sep 21, 2020 06:12am
- A bill is being promoted to strengthen the guarantee of expensive anticancer drugs for cancer patients by establishing a cancer management fund. The goal is to improve the reality that patients are deprived of treatment opportunities due to delays in health insurance payments for innovative treatments such as immune anticancer drugs due to limitations in health insurance finances. On the 17th, Lee Jong Seong, a member of People Power Party, announced that he had proposed a partial amendment to the Cancer Control Act. The bill was submitted to the National Assembly on the 16th. He pointed out that if the national security of innovative anticancer drugs is not properly secured, treatment opportunities and options vary depending on the economic level. His opinion is that the priority of health insurance for anticancer drugs with high social demand should be raised, and separate financial support should be made if financial resources are insufficient. Accordingly, he proposed a bill to strengthen support for cancer patients and establish a cancer management fund as a source of funding for cancer screening, medical expenses, and cancer research and treatment projects. He said, "Protecting the lives and safety of the people is the basic duty of the government, and having a therapeutic safety net that meets the level of the Korean economy should be the core oriented value of health policy."
- Policy
- Sinopharm COVID-19 vaccine, not considered to be introduced
- by Kim, Jung-Ju Sep 18, 2020 06:29am
- Although China is in the midst of developing COVID-19 treatments and vaccines, the government said that it has no plans to import domestically unless the safety and efficacy of these products are secured. Far from being included in the plan to secure 30 million domestic patients, it means that domestic introduction itself is impossible. Kang-lip Kim, Vice Health Minister for the Central Disaster and Safety Countermeasure Headquarters for COVID-19, clarified this position through a Q&A briefing on the morning of the 16th. In order to accelerate the end of COVID-19, the government is currently approaching the 'two-track' method of supporting domestic development and securing quantities of foreign products in relation to treatments and vaccines. When it was introduced in Korea, it also planned to secure 30 million patients. China is also strengthening R&D for the development and export of domestic drugs and vaccines, among which, interest is emerging as to whether it is possible to introduce a vaccine developed by Sinopharm in Korea. Regarding this, Kim said, "Vaccines are much more difficult to verify for safety than other drugs. As we have not yet secured safety and efficacy data for vaccines being developed by Chinese pharmaceutical company Sinopharm, we will not review them in detail." Since there is no data on the safety and effectiveness of Sinopharm, it is not even reviewed whether it is introduced or not, and if the review is complete, it is possible to review domestic introduction or securing of quantity itself. He said, "although the securing of 30 million people has not yet been specifically structured, and it is not in the stage of confirming the so-called 'portfolio', various consultations are ongoing with pharmaceutical companies developing vaccines."
- Policy
- Jeil, started commercialization of JLP-1401
- by Lee, Tak-Sun Sep 17, 2020 06:29am
- Telmiduo Plus by JeilJeil has begun commercializing a high blood pressure-hyperlipidemia three-drug, credit-quantity formulation. It is a formulation that combines Telmisartan-Amlodipine-Rosuvastatin, and is known as a new product of Telmiduo Plus, which Jeil is already launching. The MFDS approved the phase I clinical trial protocol of JLP-1401 submitted by Jeil on the 10th. In this clinical trial, the pharmacokinetic properties and safety of Telmisartan/Amlodipine and Rosuvastatin and JLP-1401 administration will be compared and evaluated in healthy adult volunteers. JLP-1401 is also the name of Telmiduo Plus, which was approved by Jeil in May 2018. Telmiduo Plus has three doses with Telmisartan-Amlodipine-Rosuvastatin dosages of '40/5/10mg', '80/10/20mg' and '80/5/10mg' respectively. Jeil directly develops and supplies contract production to Samjin, Unimed, Hana, and Myungmoon. However, Rosuvastatin 5mg is missing, which has been evaluated as being inferior in market competitiveness. Both Yuhan and Ildong, which produce the same generics, are releasing products containing Rosuvastatin 5mg. In addition, Rosuvastatin 5mg was analyzed that the rate of reaching the target LDL-C control treatment target was high at 83.3% for males and 92.9% for females, even in a study of 1,851 Korean patients. Accordingly, it seems that Jeil is developing an additional combination drug containing Rosuvastatin 5mg. This is because Twynsta 80.5mg, a combination of Telmisartan-Amlodipine, and Crestor 5mg, containing Rosuvastatin are used as reference drugs for this clinical trial. When new products are completed, it is expected that market competitiveness will improve and production will increase. A total of 40 products of Telmisartan-Amlodipine-Rosuvastatin were approved. According to UVIST, in the first half of this year, Ildong's Telostop Plus recorded about ₩1.6 billion, Yuhan's Duowell A about ₩900 million, and Jeil's Telmiduo Plus about ₩800 million.
